SE505258C2 - Nya dihydrokloridhydrat av 7-(]0a]-(2aminotiazol-4-yl)-]0a]- (Z)-metoxiiminoacetamido)-3-((1-metylpyrrolidino)-metyl)-3- cefem-4-karboxylsyra i kristallin form - Google Patents
Nya dihydrokloridhydrat av 7-(]0a]-(2aminotiazol-4-yl)-]0a]- (Z)-metoxiiminoacetamido)-3-((1-metylpyrrolidino)-metyl)-3- cefem-4-karboxylsyra i kristallin formInfo
- Publication number
- SE505258C2 SE505258C2 SE8900173A SE8900173A SE505258C2 SE 505258 C2 SE505258 C2 SE 505258C2 SE 8900173 A SE8900173 A SE 8900173A SE 8900173 A SE8900173 A SE 8900173A SE 505258 C2 SE505258 C2 SE 505258C2
- Authority
- SE
- Sweden
- Prior art keywords
- methyl
- aminothiazol
- water
- cephem
- salt
- Prior art date
Links
- -1 aminothiazol-4-yl Chemical group 0.000 title claims abstract description 10
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 title claims description 13
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 5
- 229960003646 lysine Drugs 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000006069 physical mixture Substances 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 3
- 235000011007 phosphoric acid Nutrition 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 150000004682 monohydrates Chemical class 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 150000004683 dihydrates Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007972 injectable composition Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 description 4
- 238000002411 thermogravimetry Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HQOQSFITXGQQDM-SSDOTTSWSA-N methyl (6R)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound COC(=O)C1=CCS[C@@H]2CC(=O)N12 HQOQSFITXGQQDM-SSDOTTSWSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/144,899 US4910301A (en) | 1985-08-05 | 1988-01-19 | Cefepime cephalosporin salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8900173D0 SE8900173D0 (sv) | 1989-01-18 |
| SE8900173L SE8900173L (en) | 1989-01-18 |
| SE505258C2 true SE505258C2 (sv) | 1997-07-21 |
Family
ID=22510643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8900173A SE505258C2 (sv) | 1988-01-19 | 1989-01-18 | Nya dihydrokloridhydrat av 7-(]0a]-(2aminotiazol-4-yl)-]0a]- (Z)-metoxiiminoacetamido)-3-((1-metylpyrrolidino)-metyl)-3- cefem-4-karboxylsyra i kristallin form |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US4910301A (hu) |
| JP (1) | JPH0725768B2 (hu) |
| KR (1) | KR950003612B1 (hu) |
| AT (1) | AT399878B (hu) |
| AU (1) | AU615509B2 (hu) |
| BE (1) | BE1002749A5 (hu) |
| CA (1) | CA1298288C (hu) |
| CY (1) | CY1663A (hu) |
| CZ (1) | CZ281602B6 (hu) |
| DD (2) | DD284807A5 (hu) |
| DE (1) | DE3901359A1 (hu) |
| DK (1) | DK162054C (hu) |
| EG (1) | EG18749A (hu) |
| ES (1) | ES2012948A6 (hu) |
| FI (1) | FI86854C (hu) |
| FR (1) | FR2626003B1 (hu) |
| GB (1) | GB2213819B (hu) |
| GR (1) | GR1001218B (hu) |
| HK (1) | HK72292A (hu) |
| HU (1) | HU205940B (hu) |
| IE (1) | IE67447B1 (hu) |
| IT (1) | IT1229528B (hu) |
| LU (1) | LU87432A1 (hu) |
| NL (1) | NL192266C (hu) |
| NZ (1) | NZ227605A (hu) |
| OA (1) | OA09227A (hu) |
| PT (1) | PT89474B (hu) |
| SE (1) | SE505258C2 (hu) |
| SG (1) | SG75492G (hu) |
| SK (1) | SK281768B6 (hu) |
| YU (1) | YU221188A (hu) |
| ZA (1) | ZA89407B (hu) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5244891A (en) * | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| EP0376185B1 (en) * | 1988-12-27 | 1994-08-17 | Chugai Seiyaku Kabushiki Kaisha | Process for purification of 1,2-bis(nicotinamido)propane |
| CA2011116C (en) * | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
| DE3919259A1 (de) * | 1989-06-13 | 1990-12-20 | Hoechst Ag | Kristalline cephem-saeureadditionssalze und verfahren zu ihrer herstellung |
| US5698703A (en) * | 1991-09-10 | 1997-12-16 | Bristol-Myers Squibb Company | Syn-isomer of thiazolyl intermediate and process for the preparation thereof |
| IL103110A (en) * | 1991-09-10 | 1997-04-15 | Bristol Myers Squibb Co | Anhydrous process for preparing cefepime dihydrochloride hydrate |
| YU81692A (sh) * | 1991-09-10 | 1995-03-27 | Bristol-Myers Co. | Postupak za proizvodnju cefalosporinskog antibiotika |
| US5594129A (en) * | 1991-09-10 | 1997-01-14 | Bristol-Myers Squibb Company | Process for the preparation of a cephalosporin antibiotic |
| CA2099692C (en) * | 1992-07-24 | 2003-09-30 | Gary M. F. Lim | Process for preparing cephalosporin intermediates |
| US5391729A (en) * | 1992-09-08 | 1995-02-21 | Bristol-Myers Squibb Company | Crystalline dihydrate of a cephalosporin salt |
| US5401842A (en) * | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
| CA2101571A1 (en) * | 1992-09-08 | 1994-03-09 | Elizabeth A. Garofalo | Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof |
| JPH0840907A (ja) | 1994-08-03 | 1996-02-13 | Meiji Seika Kaisha Ltd | セファロスポリン注射剤 |
| WO2005094800A2 (en) * | 2004-03-31 | 2005-10-13 | Lupin Ltd. | A co-precipitated cefepime composition and process for preparation thereof |
| US20070111980A1 (en) * | 2004-07-16 | 2007-05-17 | Bandi Parthasaradhi Reddy | Process for preparing pure cephalosporine intermediates |
| ITMI20051684A1 (it) * | 2005-09-13 | 2007-03-14 | Harvest Lodge Ltd | Procedimento per la produzione del dicloridrato di amminoacidi |
| ITMI20060422A1 (it) * | 2006-03-09 | 2007-09-10 | Harvest Lodge Ltd | Procedimento diretto per la produzione del dicloridrato di un amminoacido |
| US8151846B2 (en) * | 2006-12-15 | 2012-04-10 | Center Line Wheel Corporation | Wheel having inner bead-lock |
| AR077320A1 (es) * | 2009-07-20 | 2011-08-17 | Intervet Int Bv | Metodo para la preparacion de particulas de cefquinoma y formulaciones farmaceuticas que las comprenden. |
| CN103304580B (zh) * | 2013-06-09 | 2014-07-09 | 四川省惠达药业有限公司 | 一种盐酸头孢吡肟化合物、其制备方法及其药物组合物 |
| WO2017096472A1 (en) * | 2015-12-10 | 2017-06-15 | Naeja-Rgm Pharmaceuticals Inc. | Cephem compounds, their production and use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029655A (en) * | 1975-04-11 | 1977-06-14 | Eli Lilly And Company | Method of preparing stable sterile crystalline cephalosporins for parenteral administration |
| JPS55151588A (en) * | 1979-05-14 | 1980-11-26 | Takeda Chem Ind Ltd | Preparation of cephalosporin salt crystal |
| IT1145686B (it) * | 1979-05-25 | 1986-11-05 | Glaxo Group Ltd | Intermedi per la preparazione di antibiotici cefalosporinici e procedimento per prepararli |
| US4329453A (en) * | 1979-10-02 | 1982-05-11 | Glaxo Group Limited | Cephalosporin antibiotic |
| US4406899A (en) * | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
| CA1213882A (en) * | 1982-03-04 | 1986-11-12 | Jun Okumura | Cephalosporins |
| US4525473A (en) * | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
| US4537959A (en) * | 1984-03-26 | 1985-08-27 | Eli Lilly And Company | Crystalline cephalosporin antibiotic salt |
| US4751295A (en) * | 1984-04-09 | 1988-06-14 | Bristol-Myers Company | Cephalosporin derivatives |
| US4749694A (en) * | 1984-04-26 | 1988-06-07 | Merck & Co., Inc. | Novel lysine esters used as absorption |
| FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
| US4808617A (en) * | 1985-12-18 | 1989-02-28 | Bristol-Myers Company | Lyophilized or precipitated cephalosporin zwitterion and salt combination |
| US4791196A (en) * | 1986-09-26 | 1988-12-13 | Sankyo Company Limited | Crystalline cephem carboxylic acid addition salt |
-
1988
- 1988-01-19 US US07/144,899 patent/US4910301A/en not_active Expired - Lifetime
- 1988-12-06 YU YU02211/88A patent/YU221188A/xx unknown
-
1989
- 1989-01-12 NZ NZ227605A patent/NZ227605A/en unknown
- 1989-01-13 SK SK243-89A patent/SK281768B6/sk unknown
- 1989-01-13 CZ CS89243A patent/CZ281602B6/cs not_active IP Right Cessation
- 1989-01-16 ES ES8900146A patent/ES2012948A6/es not_active Expired - Fee Related
- 1989-01-16 FI FI890213A patent/FI86854C/fi not_active IP Right Cessation
- 1989-01-17 IT IT8947539A patent/IT1229528B/it active
- 1989-01-17 GR GR890100025A patent/GR1001218B/el not_active IP Right Cessation
- 1989-01-18 LU LU87432A patent/LU87432A1/fr unknown
- 1989-01-18 FR FR8900553A patent/FR2626003B1/fr not_active Expired - Lifetime
- 1989-01-18 EG EG2189A patent/EG18749A/xx active
- 1989-01-18 DD DD89333774A patent/DD284807A5/de unknown
- 1989-01-18 HU HU89185A patent/HU205940B/hu unknown
- 1989-01-18 CA CA000588576A patent/CA1298288C/en not_active Expired - Lifetime
- 1989-01-18 DK DK020789A patent/DK162054C/da not_active IP Right Cessation
- 1989-01-18 AT AT0008589A patent/AT399878B/de not_active IP Right Cessation
- 1989-01-18 KR KR1019890000493A patent/KR950003612B1/ko not_active IP Right Cessation
- 1989-01-18 OA OA59509A patent/OA09227A/xx unknown
- 1989-01-18 GB GB8901073A patent/GB2213819B/en not_active Expired - Lifetime
- 1989-01-18 DD DD89325118A patent/DD283397A5/de unknown
- 1989-01-18 PT PT89474A patent/PT89474B/pt not_active IP Right Cessation
- 1989-01-18 IE IE14489A patent/IE67447B1/en not_active IP Right Cessation
- 1989-01-18 ZA ZA89407A patent/ZA89407B/xx unknown
- 1989-01-18 DE DE3901359A patent/DE3901359A1/de active Granted
- 1989-01-18 NL NL8900111A patent/NL192266C/nl not_active IP Right Cessation
- 1989-01-18 BE BE8900051A patent/BE1002749A5/fr active
- 1989-01-18 SE SE8900173A patent/SE505258C2/sv not_active IP Right Cessation
- 1989-01-19 JP JP1008776A patent/JPH0725768B2/ja not_active Expired - Lifetime
- 1989-01-19 AU AU28623/89A patent/AU615509B2/en not_active Expired
-
1992
- 1992-07-24 SG SG754/92A patent/SG75492G/en unknown
- 1992-09-24 HK HK722/92A patent/HK72292A/xx not_active IP Right Cessation
-
1993
- 1993-05-14 CY CY1663A patent/CY1663A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE505258C2 (sv) | Nya dihydrokloridhydrat av 7-(]0a]-(2aminotiazol-4-yl)-]0a]- (Z)-metoxiiminoacetamido)-3-((1-metylpyrrolidino)-metyl)-3- cefem-4-karboxylsyra i kristallin form | |
| KR840001776B1 (ko) | 세프타지딤 펜타하이드레이트의 제조방법 | |
| DK166211B (da) | Krystalliseret cephem-syreadditionssalt, dets fremstilling og anvendelse | |
| KR930003121B1 (ko) | 세팔로스포린염의 제조방법 | |
| AU621040B2 (en) | Crystallized cephem-acid addition salts, and a process for the preparation thereof | |
| CA1043261A (en) | Cephalosporin-type antibiotic composition | |
| US5244891A (en) | Injectable compositions of cefepime dihydrochloride hydrate | |
| US4994451A (en) | Cephalosporin salts and injectable compositions | |
| EP0261990B1 (en) | Crystalline cephem carboxylic acid addition salt | |
| JPWO2004085443A1 (ja) | ７−［２−（２−アミノチアゾール−４−イル）−２−ヒドロキシイミノアセトアミド−３−ビニル−３−セフェム−４−カルボン酸（シン異性体）の新規結晶およびその製造方法 | |
| JPS609698B2 (ja) | 経口投与用セフアロスポリン剤 | |
| JPH06247974A (ja) | セファロスポリン塩及びその製造方法 | |
| HU182676B (en) | Process for producing 6-beta-square bracket-2-bracket-2-comma above-methyl-phenoxy-carbonyl-bracket closed-2-thien-3-comma above-yl-acetamido-square bracket closed-2,2-dimethyl-pename-carboxylic acid and alkali salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |